PRME

Prime Medicine, Inc. PRME

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,789 of 2,925

Why it scores 17Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Net income

$-42.11M

Quarter to Jun 30

Free cash flow

$-41.09M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$392.91M total
Alphabet Inc.
$61.12M0.0%
BlackRock, Inc.
$35.43M+12.9%
ARK Investment Management LLC
$30.81M+33.6%
STATE STREET CORP
$27.96M+19.4%
T. Rowe Price Investment Management, Inc.
$19.33M-4.5%
VANGUARD CAPITAL MANAGEMENT LLC
$16.69M+1.1%
BALYASNY ASSET MANAGEMENT L.P.
$14.65M-3.7%
GOLDMAN SACHS GROUP INC
$12.66M+253.5%
Casdin Capital, LLC
$11.69M0.0%
Woodline Partners LP
$11.08M0.0%
UBS Group AG
$10.31M-3.2%
GEODE CAPITAL MANAGEMENT, LLC
$10.01M-1.1%
Sumitomo Mitsui Trust Holdings, Inc.
$8.90M-17.9%
Nikko Asset Management Americas, Inc.
$8.86M-18.2%
CITADEL ADVISORS LLC
$7.58M+510.8%
ADAR1 Capital Management, LLC
$7.37M+1.2%
FMR LLC
$6.50M-0.4%
TWO SIGMA INVESTMENTS, LP
$5.63M-3.1%
Redmile Group, LLC
$5.13M-12.6%
FARALLON CAPITAL MANAGEMENT LLC
$4.58M0.0%
Jump Financial, LLC
$4.58MNew
BANK OF AMERICA CORP /DE/
$3.62M+70.1%
VANGUARD PORTFOLIO MANAGEMENT LLC
$3.55M+11.6%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$3.42M+1.1%
NORTHERN TRUST CORP
$3.37M+2.9%
See all 188 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PRME

Earnings Per Share

13fpro.ai/company/PRME

Loading ratio trend…

PRME key financials by period

Reported revenue, net income and operating margin by fiscal year, from Prime Medicine, Inc.'s annual filings on SEC EDGAR.

Prime Medicine, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$4.6M$-201.1M—
FY 2024$3.0M$-195.9M—
FY 2020$5.2M$-3.4M-17.9%
Source: PRME filings on SEC EDGAR →

Companies similar to PRME

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

PRME insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Prime Medicine, Inc. (PRME): stock profile, AI score and financials

Prime Medicine, Inc. (PRME) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRME at 17.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,789 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (1.1) and profitability (1.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Prime Medicine, Inc. reports net income of $-42.1M, free cash flow of $-41.1M. Top institutional holders of PRME by reported 13-F value include Alphabet, BlackRock, ARK Investment Management, based on the most recent SEC filings. PRME trades on the Nasdaq exchange and files with the SEC under CIK 1894562. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRME daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Prime Medicine, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1894562 →